PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 

Anavex Life Sciences Corp.

Press Releases

Click on the press release below to view it in its entirety

Receive press releases from Anavex Life Sciences Corp.: By Email RSS Feeds:
Anavex Life Sciences Corp. has selected FORENAP Pharma EURL as the contract research organization (CRO). - October 02, 2009
Anavex Life Sciences Corp. today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. - September 23, 2009
Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) today announced the immediate appointment of Hervé de Kergrohen, MD, MBA, as its Chief Executive Officer (CEO) and director. Dr. de Kergrohen is an accomplished senior executive who has successfully founded and developed numerous... - June 18, 2009
Anavex Life Sciences Corp. today announced the appointment of Dr. Mark A. Smith, Ph.D., FRCPath, to its scientific advisory board. - February 12, 2009
Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) has signed an agreement with organic chemistry services provider Syntagon AB (“Syntagon”) for the scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is scheduled... - February 04, 2009
Anavex Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that the anti-amnesic and neuroprotective effects of ANAVEX 1-41 are detailed in a paper published... - December 19, 2008
Anavex Life Sciences Corp., a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, was selected to present its latest results with ANAVEX 1-41 at Neuroscience 2008, the 38th annual meeting of the Society for... - December 17, 2008
Anavex completes successful preclinical studies on Anavex 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease. - September 04, 2008
Anavex Life Sciences presented its new findings of its ANAVEX 1-41 compound targeting Alzheimer's disease at ICAD (July 26 to 31, 2008). - August 02, 2008
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) announces its participation at the International Conference on Alzheimer's Disease 2008 (July 26-31, 2008, Chicago, USA), where it will present results obtained with Anavex 1-41 demonstrating a protective effect against the neurotoxicity of... - July 15, 2008
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced the appointment of David L. Tousley, CPA, MBA, to its Board of Directors. Mr. Tousley is an accomplished professional with many years of experience as a senior financial and operations executive in start-up and established... - June 20, 2008
Anavex Life Sciences Corp. ("ANAVEX'') (OTC BB:AVXL.OB) today announced the appointment of Alison Ayers to its Board of Directors. Ms. Ayers is currently the Worldwide Commercial Head for Oncology at Pfizer, with responsibility for Pfizer's oncology portfolio, which includes more than 20 drug candidates... - May 23, 2008
Anavex Life Sciences Corp. achieved significant development of its lead drug candidates and growth of its management and scientific teams during 2007. - January 24, 2008
Results from animal model testing demonstrate ANAVEX 1-41 has significant neuroprotective and anti-amnesic benefits. - January 16, 2008
ANAVEX 7-1037 has been shown to kill human HCT116 colon cancer cells in advanced pre-clinical studies. - January 16, 2008
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL - News) announces the appointment of Dr. Cameron Durrant to its Board of Directors. - January 16, 2008
Press Releases 1 - 16 of 16 Page: 1
Promote Your Business